Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering.
A groundbreaking review of mesothelin-targeted immunotherapy candidates has recently been added to the expansive catalogue of research publications. Mesothelin, a cell surface protein found to be overexpressed in numerous cancer types, presents a promising biomarker for targeted immunotherapy treatment. Its restricted expression in healthy tissues and high prevalence in malignancies such as mesothelioma, ovarian, and pancreatic cancers underscore mesothelin's potential for precision medicine.
This thorough review shines a spotlight on significant progress in the field and maps out the trajectory of ongoing trials and research. It highlights next-generation mesothelin-targeted therapies that show promise in circumventing the limitations of previous drug modalities.
Continued innovation in this area is driven by the critical need for effective treatments against high-grade malignancies, with some studies showing mesothelin expression in up to 80% of ovarian cancers. The review also offers insight into the safety profile of anti-mesothelin therapies, confirming their specificity and limited toxicity due to minimal expression of mesothelin in non-cancerous tissue.
The newly launched pipeline review offers an in-depth examination of the landscape, focusing on:
Advancements in Mesothelin-Targeted Immunotherapies
For more information about this report visit https://www.researchandmarkets.com/r/axl1hi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.